Stock Price & Analysis

Based on the provided data and recent market analysis, here's a comprehensive evaluation of ABBV stock:

Technical Analysis

The stock shows strong bullish momentum with recent price action forming higher highs and higher lows. ABBV is trading above all major moving averages (5-day: $197.89, 10-day: $194.86, 20-day: $188.51), indicating robust upward momentum. The RSI at 77.28 suggests slightly overbought conditions but remains supported by strong fundamentals.

Fundamental Strength

AbbVie demonstrates compelling value metrics:

• Forward P/E of 16x based on 2025 projected EPS
• Attractive 3.3% dividend yield
• 53 consecutive years of dividend growth (Dividend King status)

Growth Catalysts

1. Strong Revenue Outlook:

• Management projects mid-single-digit revenue growth for 2025
• Skyrizi and Rinvoq combined sales expected to reach $24B in 2025 and exceed $31B by 2027
• Clear growth runway through 2029 with no major patent expirations

2. Earnings Momentum:

• 2025 adjusted EPS guidance: $12.12-$12.32 (21% YoY growth)
• Q4 2024 results exceeded expectations with $15.1B revenue (+5.6% YoY)

Analyst Sentiment

• Consensus rating: "Moderate Buy" from 26 analysts
• 16 Strong Buy, 2 Moderate Buy, 8 Hold ratings
• Mean price target: $204.32 (+7.6% upside potential)
• Street-high target: $227 (+19.5% upside)

Conclusion

SELL signal at current levels ($173.45) due to:

1. Overbought technical conditions (RSI >70)
2. Stock trading near resistance levels
3. Recent strong rally (+8% YTD) suggesting potential short-term pullback

Consider re-entering on pullbacks to support levels around $165-170 range for long-term investment, given strong fundamentals and growth outlook.

Based on the provided data and recent analyst reports, here's a comprehensive price prediction for ABBV stock in 2025:

Technical Analysis

Price Target Analysis AbbVie's stock shows strong technical momentum with:

• Current trading level around $202
• RSI at 77.28 indicating overbought conditions but strong momentum
• MACD positive at 5.79 with bullish divergence
• Strong support at Fibonacci level of $189.70

Fundamental Drivers

• Management projects adjusted EPS of $12.12-$12.32 for 2025, representing 21% growth from 2024
• Skyrizi and Rinvoq combined sales expected to reach $24 billion in 2025 and exceed $31 billion by 2029
• Mid-single digit revenue growth projected for 2025
• No significant patent losses expected through 2029

2025 Price Prediction Based on the analysis, ABBV stock is expected to reach $215-220 by end of 2025, supported by:

• Forward P/E of 16x on 2025 consensus EPS of $12.41
• Strong product pipeline and growth trajectory
• Continued momentum in immunology portfolio

The stock has potential upside of 7-19% from current levels, with analysts' price targets ranging from $204 to $227.

The S1 support level for ABBV Stock is $192.96 ,The R1 resistant level for ABBV Stock is $205.29.

As of the end of day on 2025-02-28, the price of ABBV Stock was $205.6.

The target price for ABBV Stock according to analyst rating is 207.83, with the highest price target at 239.00 and the lowest at 165.00. Analysts have a Moderate Buy rating on ABBV Stock overall.

The market cap of ABBV is $361.9B.

Based on the provided data and recent market analysis, here's a comprehensive evaluation of ABBV's valuation:

Technical Analysis

The stock is showing strong momentum with RSI at 77.28 and trading above both its 20-day (188.51) and 200-day (179.83) moving averages, indicating a bullish trend. The stock is currently trading in the upper Bollinger Band range with a BBP of 0.75, suggesting some potential for consolidation.

Fundamental Valuation

The stock appears fairly valued considering:

• P/E ratio has increased from 24.39 in Q4 2022 to 57.00 in Q4 2023, reflecting market confidence in future growth
• EV/EBITDA of 12.61 in Q4 2023 remains reasonable for the pharmaceutical sector
• Price-to-Sales ratio of 5.06 indicates premium pricing but justified by strong market position

Growth Catalysts

1. Strong Revenue Replacement:

• Skyrizi and Rinvoq combined sales reached $17.7B in 2024
• Expected to grow to $24B in 2025
• Projected to exceed $31B by 2029

2. Earnings Growth:

• 2025 EPS projected at $12.12-$12.32
• Represents 21% increase from 2024
• Consistent earnings beat in last four quarters

Analyst Consensus:

• 26 analysts coverage
• 16 Strong Buy
• 2 Moderate Buy
• 8 Hold
• Mean price target: $204.32 (7.6% upside potential)
• Street-high target: $227 (19.5% upside)

Conclusion: ABBV appears slightly overvalued at current levels based on historical metrics, but the company's strong growth prospects, successful Humira replacement strategy, and positive analyst sentiment suggest the premium valuation is justified. The stock's defensive characteristics and 3.3% dividend yield provide additional support.

AbbVie Inc. is a diversified research-based biopharmaceutical company. The Company is engaged in the research and development, manufacturing, commercialization and sale of medicines and therapies. It offers products in therapeutic categories, including immunology products, which include Humira, Skyrizi and Rinvoq; oncology products, which include Imbruvica, Venclexta/Venclyxto, Epkinly and Elahere; aesthetics products, which include Botox Cosmetic, The Juvederm Collection of Fillers and others; neuroscience products, which include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy and Qulipta; eye care products, which consists of Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis and Other eye care, and other key products, which include Mavyret/Maviret, Creon, Lupron, Linzess/Constella and Synthroid. Its products are sold to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies and independent retailers.

Based on the provided data and references, I'll analyze ABBV's potential price in 2030:

Price Target Analysis for 2030

AbbVie's stock is projected to reach approximately $438 by 2030, driven by continued growth in its immunology portfolio and strategic acquisitions. This represents a potential upside of about 117% from the current price of $202.08.

The key drivers supporting this projection include:

Growth Catalysts:

1. Post-Humira Strategy Success:

• Skyrizi and Rinvoq combined sales expected to exceed $31 billion by 2027, up from previous guidance of $27 billion
• Strong momentum in neuroscience portfolio with high single-digit growth through 2029

2. Strategic Acquisitions:

• ImmunoGen acquisition strengthening oncology portfolio
• Cerevel Therapeutics acquisition ($8.7B) enhancing neuroscience pipeline

Risk Factors:

• Patent expirations for key drugs
• Regulatory challenges
• Competition in immunology space
• Integration risks from recent acquisitions

Analyst Consensus:

• Current consensus rating is "Moderate Buy" with 16 Strong Buy ratings
• Mean price target of $204.32 for near term
• Long-term growth projections supported by pipeline strength and acquisition strategy

ABBV has a total of 50000 employees.